The global graft versus host disease (GvHD) treatment market size is expected to secure USD 5,960.7 million by 2033 while expanding at a CAGR of 8.2%.
The GvHD treatment market is experiencing a steady growth in corticosteroids and combination therapies for graft-versus-host disease in HCT patients boosting the market for (GvHD) treatment. The market is likely to hold a value of USD 2,713.6 million in 2023. From 2018 to 2022, the market displayed a growth rate of 8.2%.
Allogeneic hematopoietic cell transplant patients may benefit from recent advancements in overall survival rate and acute graft-versus-host disease (GVHD) severity levels, however, several challenges must be addressed. In addition, newer medications such as Jakafi and Rezurock have recently been approved for the prevention and treatment of chronic (GVHD) and may provide a greater benefit than older medications.
| Data Points | Key Statistics |
|---|---|
| Graft Versus Host Disease (GvHD) Treatment Market Value (2023) | USD 2,713.6 million |
| Graft Versus Host Disease (GvHD) Treatment Market Forecast Value (2033) | USD 5,960.7 million |
| Estimated Growth Rate (2023 to 2033) | 8.2% CAGR |
For treating adults and pediatric patients with GVHD, Orencia (abatacept) was approved by the United States Food and Drug Administration in December 2021. In addition to treating autoimmune disorders, Orencia is also used to prevent them. T-cells are a key component of acute (GVHD), and this drug circumvents their attack by specifically binding to and modulating one of the main costimulation signals sent by these cells.
This prevents a full activation of T-cells, which prevents acute (GVHD) from occurring. Several new approaches are being evaluated by doctors to prevent (GVHD) in the future.
Approval of Orencia is expected to make stem cell transplants more accessible to a larger number of cancer patients and people with blood disorders, particularly people from diverse ethnic backgrounds. To improve treatment response, future treatments may include immunosuppression and other treatment agents, such as regenerative or tissue-repairing agents to the market.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
A healthy CAGR is expected to be observed for graft versus host disease treatment during the forecast period. As innovative technologies are developed, and cancer patients seek out chemotherapy treatments, the graft versus host disease (GvHD) treatment market is expected to expand from 2023 to 2033.
Cancer patients who are treated with chemotherapy are the main driving force behind the graft versus host disease (GvHD) market at present. Increasing bone marrow transplants to treat specific cancers is also fueling the global graft versus host disease market.
Human health products have become increasingly innovative and effective in recent decades. Growth in graft versus host disease (GvHD) is projected to be considerably impacted by the use of allogeneic stem cell transplants.
To stay competitive, key players focus on introducing new drugs to the market. As a result of the high investments made by the public and private sectors in research and development technology and infrastructure, it is expected that the market is expected to be provided with lucrative opportunities shortly.
A global economy that focuses on advancing technology and innovation has the potential to restore growth and ensure the future competitiveness of the pharmaceutical industry by investing in innovation and research.
| Trend | The surging rate of acute GvHD, increasing rate of hematopoietic stem cell treatment, and rising number of pipeline drugs are catalyzing the demand for graft versus host disease (GvHD) treatment. |
|---|---|
| Supporting News |
|
| Trend | Governments and industry players are heavily investing in research and development. The positive outcomes of these clinical trials are expected to result in new treatments, which are projected to propel industry growth. |
|---|---|
| Supporting News | In June 2021, Equillium Inc. stated the completion of an End-of-Phase 1 meeting with the United States FDA for itolizumab in the treatment of aGvHD patients. |
| Trend | Research studies to elevate the effectiveness of corticosteroids in the treatment |
|---|---|
| Supporting News | In June 2022, a clinical trial was underway. It is a multicenter, open-label, two-arm randomized trial that assesses if the addition of ruxolitinib clubbed with corticosteroids is greater than corticosteroids to treat newly diagnosed aGvHD. A 50% response rate was reported for first-line therapy. |
Global graft versus host disease (GvHD) market growth is likely to be hindered by costs associated with recent clinical trials and authorizations. Using steroids in the treatment of (GvHD) immune diseases, skin diseases, and other conditions may result in side effects such as glucose levels increasing, fluid retention, mood problems, appetite disorders, and stomach pain.
The use of steroids over a long period has been linked to diabetes, infection, muscle weakness, and even cancer.
| Region and their Market Share % (2022) | Countries and their Share (2022)/ Forecast CAGR % |
|---|---|
| North America had a 34.7% Share | The United States had a 30.7% Market Share |
| Europe had a 26.7% Share |
|
As per the research, the global graft versus host disease (GvHD) treatment market is expected to be dominated by North America during the forecast period. In 2023, the region is expected to secure more than 34.7% of the total market share. As a result of a well-established medical infrastructure and the proliferation of major key players in the region, the region has become a dominant market for (GvHD) treatments.
The United States is expected to contribute the most to the development of the market during the forecast period. Growing awareness of (GVHD) has boosted the market for (GvHD) treatments in this region. New medicines are expected to propel the market growth during the forecast period. Additionally, the regulatory authority's approval for various medicines in the market also contributes to the growth of the region.
For instance, on September 22, 2021, the FDA approved Ruxolitinib for chronic graft-versus-host disease ((GVHD)) in adults and children over 12 years of age who have failed one or more lines of systemic therapy. REACH-3 (NCT03112603) evaluated Ruxolitinib's efficacy as a treatment for corticosteroid-refractory chronic (GVHD) after allogeneic stem cell transplantation compared with the best available therapy (BAT) on the market.
According to the analysis, the Europe GvHD treatment market is projected to be a prominent market during the forecast period. It is estimated that the region is going to hold more than 26.5% of the total market share in 2023. The growth of the market can be attributed to the rapid development of the food and beverage sector in the region.
Growing awareness, the availability of chemotherapies, and the adoption of advanced cancer treatment technologies drive the market for graft versus host disease (GvHD) treatment in these regions. In addition, the rise in the aging population, scientific advancements, and clinical trials are expected to grow the market for GvHD treatment in the market.
According to Future Market Insights, monoclonal antibodies are expected to gain significant market share in the upcoming years. With the rapid development of pharmaceuticals and clinical trials, along with the expanding treatment for chronic diseases, the worldwide market is set for continued expansion shortly.
The increasing number of cancer cases in various regions has fuelled the growth of this GvHD treatment market in recent years. Due to their specialization in targeted cancer therapies in the medical sector, monoclonal antibodies are in high demand due to their unique properties.
Some monoclonal antibodies are also immunotherapies since they are effective in fighting cancer by turning the immune system against the disease. These treatment types are therefore growing in the market.
The use of various treatments for GvHD is expected to drive the market and account for the greatest share in 2023. Globally, the market is expected to expand at a significant CAGR, attracting private and public investments to this market.
Ruxolitinib is becoming more widely used as an alternative treatment option for acute graft versus host disease (GvHD), which reduces the need for hospitalization unless there are complications. Increasing immunosuppression is often successfully achieved through the administration of oral or intravenous steroid medications.
The severe complications of acute graft-versus-host disease (GVHD) continue to hinder the success of allogeneic hematopoietic stem cell transplants (HSCTs). As a treatment when prophylaxis fails or remains suboptimal, the ability to prevent (GVHD) prophylaxis is crucial. The most commonly prescribed regimen for prophylaxis of (GVHD) still consists of a calcineurin inhibitor in combination with methotrexate.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Healthcare continues to be a flourishing sector, and the demand for safe and effective graft-versus-host-disease medications is on the rise. Numerous innovative medicine solutions have been introduced in the medical field to reduce side effects and improve long-term outcomes, including the incorporation of graft versus host disease (GvHD) treatment. As start-ups realize their potential, they are firmly establishing themselves on the global market.
Some notable graft versus host disease start-up manufacturers are as follows:
The market is valued at USD 2.7 billion in 2023.
Astellas Pharma, Mesoblast Ltd, and Equillium, Inc. are key market players.
The market will reach USD 5.9 billion by 2033.
Increasing cases of acute GvHDwill drive the market prospects.
Monoclonal antibodies segment is likely to remain preferred through 2033.
| Market Size (2024E) | USD 21.5 billion |
|---|---|
| Projected Market Size (2034F) | USD 43.2 billion |
| Value CAGR (2024 to 2034) | 7.2% |
| Market Value for 2024 | USD 52 billion |
|---|---|
| Market Value for 2034 | USD 102.4 billion |
| Forecast CAGR for 2024 to 2034 | 7% |
Explore Therapy Area Insights
View Reports
Graft Versus Host Disease (GvHD) Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
